More and more companies are encountering added pressures to reduce costs, risks, and time-to-market while maximizing efficiencies. They have converged on a common strategy of outsourcing non-core functions. A trend is developing where companies as small as start-up biotechs to the major pharmaceutical and biopharmaceutical producers are outsourcing their peptide production needs. Whether a company needs research or GMP-grade materials, they are realizing enhanced cost-effectiveness and efficiency by doing so…
JUST PUBLISHED: "Standardized and GMP-Ready, Closed-System Processing of Expanded Adipose-Derived Stem Cells Using the Gibco CTS
Rotea System Across 2D and 3D Bioreactor Expansions." Click on the OPEN ACCESS ARTICLES tab below.
